Wedbush Comments on Geron's Q2 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN - Free Report) - Stock analysts at Wedbush increased their Q2 2025 earnings per share estimates for Geron in a research note issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will post earnings of ($0.02) per share for the quarter, up from their prior estimate of ($0.03). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.08) EPS.

Several other research analysts also recently weighed in on the company. Barclays reaffirmed an "overweight" rating and set a $4.00 target price (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and dropped their price target for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. Stifel Nicolaus dropped their target price on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. B. Riley cut Geron from a "buy" rating to a "neutral" rating and dropped their target price for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $5.06.

Geron Stock Performance

NASDAQ:GERN traded down $0.01 during trading hours on Monday, reaching $1.19. The company had a trading volume of 5,926,391 shares, compared to its average volume of 11,566,522. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm has a market cap of $757.93 million, a PE ratio of -3.72 and a beta of 0.76. The business's 50 day moving average price is $1.47 and its 200-day moving average price is $2.69. Geron has a 1-year low of $1.17 and a 1-year high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $39.60 million during the quarter, compared to the consensus estimate of $49.88 million. During the same period in the previous year, the company posted ($0.07) earnings per share. Geron's revenue for the quarter was up 12927.3% on a year-over-year basis.

Institutional Investors Weigh In On Geron

Several institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP increased its position in Geron by 947.6% during the fourth quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company's stock worth $38,940,000 after buying an additional 9,950,000 shares during the period. Braidwell LP acquired a new position in Geron during the fourth quarter worth $24,802,000. Boxer Capital Management LLC acquired a new position in Geron during the fourth quarter worth $21,240,000. Woodline Partners LP boosted its position in Geron by 64.6% during the fourth quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company's stock worth $41,019,000 after purchasing an additional 4,549,031 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company's stock worth $95,769,000 after purchasing an additional 4,516,615 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.